Education
About Us
Working with TipRanks
Follow Us
ABIONYX Pharma SA (GB:0RAG)
LSE:0RAG
RESEARCH TOOLSreports
0RAG Stock Chart & Stats
Day’s Range― - ―
52-Week Range€1.16 - €1.42
Previous CloseN/A
Volume167.00
Average Volume (3M)24.00
Market Cap
€41.58M
Enterprise Value€41.83M
Total Cash (Recent Filing)€3.23M
Total Debt (Recent Filing)€2.76M
Price to Earnings (P/E)―
Beta-0.09
Next Earnings
Sep 25, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding34,931,010
10 Day Avg. Volume40
30 Day Avg. Volume24
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)5.70
Price to Sales (P/S)0.00
P/FCF Ratio-11.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.00Price Target Upside-16.67% Downside
Rating ConsensusHold
Number of Analyst Covering0
0RAG FAQ
What was ABIONYX Pharma SA’s price range in the past 12 months?
ABIONYX Pharma SA lowest share price was €1.16 and its highest was €1.42 in the past 12 months.
What is ABIONYX Pharma SA’s market cap?
ABIONYX Pharma SA’s market cap is €41.58M.
When is ABIONYX Pharma SA’s upcoming earnings report date?
ABIONYX Pharma SA’s upcoming earnings report date is Sep 25, 2025 which is in 72 days.
How were ABIONYX Pharma SA’s earnings last quarter?
Currently, no data Available
Is ABIONYX Pharma SA overvalued?
According to Wall Street analysts ABIONYX Pharma SA’s price is currently Overvalued.
Does ABIONYX Pharma SA pay dividends?
ABIONYX Pharma SA does not currently pay dividends.
What is ABIONYX Pharma SA’s EPS estimate?
ABIONYX Pharma SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABIONYX Pharma SA have?
ABIONYX Pharma SA has 34,931,010 shares outstanding.
What happened to ABIONYX Pharma SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ABIONYX Pharma SA?
Currently, no hedge funds are holding shares in GB:0RAG
Company Description
ABIONYX Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.